Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia
NCT ID: NCT00995618
Last Updated: 2011-01-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
24 participants
INTERVENTIONAL
2009-09-30
2010-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Tranilast Alone or in Combination With Allopurinol in Subjects With Hyperuricemia
NCT01052987
Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout
NCT02252835
Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout
NCT02500641
Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria
NCT03118739
Tranilast Plus Allopurinol in Patients With Moderate to Severe Gout (TAnGO)
NCT01109121
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tranilast
Tranilast tablets
Tranilast
Tranilast tablets, 300 mg, QD
Febuxostat
Febuxostat tablets
Febuxostat
Febuxostat Tablets, 40 mg, QD
Combination
Tranilast plus febuxostat
Combination - Tranilast and Febuxostat
Tranilast, 300 mg QD; Febuxostat, 40 mg QD
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tranilast
Tranilast tablets, 300 mg, QD
Febuxostat
Febuxostat Tablets, 40 mg, QD
Combination - Tranilast and Febuxostat
Tranilast, 300 mg QD; Febuxostat, 40 mg QD
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects with hyperuricemia who are otherwise healthy
Exclusion Criteria
* Known history of gout
* Clinically significant infection at Screening
* Known sensitivity to tranilast or febuxostat
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nuon Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nuon Therapeutics
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Director, Nuon Clinical Trials Group
Role: STUDY_DIRECTOR
Nuon Therapeutics, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nuon Investigative Site
Honolulu, Hawaii, United States
Nuon Investigative Site
Evansville, Indiana, United States
Nuon Investigative Site
Dallas, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A3006GT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.